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Abstract. Viral oncoproteins that inactivate the retino- 
blastoma tumor suppressor protein (pRb) family both 
block skeletal muscle differentiation and promote cell 
cycle progression. To clarify the dependence of termi- 
nal differentiation on the presence of the different 
pRb-related proteins, we have studied myogenesis us- 
ing isogenic primary fibroblasts derived from mouse 
embryos individually deficient for pRb, p107, or p130. 
When ectopically expressed in fibroblasts lacking pRb, 
MyoD induces an aberrant skeletal muscle differentia- 
tion program characterized by normal expression of 
early differentiation markers such as myogenin and 
p21, but attenuated expression of late differentiation 
markers such as myosin heavy chain (MHC). Similar 
defects in MHC expression were not observed in cells 
lacking either p107 or p130, indicating that the defect is 
specific to the loss of pRb. In contrast to wild-type, 
pl07-deficient, or pl30-deficient differentiated myo- 
cytes that are permanently withdrawn from the cell cy- 
cle, differentiated myocytes lacking pRb accumulate in 
S and G2 phases and express extremely high levels of 
cyclins A and B, cyclin-dependent kinase (Cdk2), and 
Cdc2, but fail to readily proceed to mitosis. Administra- 
tion of caffeine, an agent that removes inhibitory phos- 
phorylations on inactive Cdc2/cyclin B complexes, spe- 
cifically induced mitotic catastrophe in pRb-deficient 
myocytes, consistent with the observation that the ma- 
jority of pRb-deficient myocytes arrest in S and G2. To- 
gether, these findings indicate that pRb is required for 
the expression of late skeletal muscle differentiation 
markers and for the inhibition of DNA synthesis, but 
that a pRb-independent mechanism restricts entry of 
differentiated myocytes into mitosis. 
S 
KELETAL muscle differentiation involves the coordi- 
nated activation of muscle-specific gene expression 
and cessation of cell division, resulting in the forma- 
tion of terminally differentiated myotubes. Studies of the 
past decade have demonstrated that the myogenic basic- 
Helix-Loop-Helix (bHLH)  ~ proteins  (i.e.,  MyoD, Myf-5, 
myogenin, and MRF-4) act in cooperation with the MEF2 
family of transcription  factors to activate muscle-specific 
gene expression (for reviews see Buckingham,  1992; Wright, 
1992;  Emerson,  1993; Sassoon,  1993; Weintraub,  1993; 
Lassar  and  Mtinsterberg,  1994; Olson  and  Klein,  1994). 
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Myf-5  and  MyoD  proteins  are  present  in  proliferating 
myoblasts and initiate a cascade of events resulting in ter- 
minal skeletal muscle differentiation when myoblasts are 
deprived of mitogens (for review see Lassar et al., 1994). 
Several hypotheses have been proposed to explain how 
the activity of the myogenic bHLH proteins is restrained 
in proliferating myoblasts; these include inhibitory phos- 
phorylation  of the  myogenic bHLH factors  (Li et  al., 
1992; Hardy et al.,  1993), inhibition  of myogenic bHLH 
function via the  Id  family of dominant-negative  bHLH 
factors (Benezra et al., 1990; Jen et al., 1992), and either 
direct or indirect inhibition by cyclin D-dependent kinases 
(Rao et al., 1994; Rao and Kohtz, 1995; Skapek et al., 1995). 
A  role  for  cyclin  D--dependent  kinases  in  controlling 
MyoD function is supported by the finding that ectopic ex- 
pression of p16, a specific inhibitor of cyclin-D/Cdk4 and 
Cdk6 kinases (Serrano et al., 1993), or p21, a more univer- 
sal inhibitor of cyclin-dependent kinases (Cdks) (Gu et al., 
1993b; Harper et al., 1993; Xiong et al., 1993), can activate 
MyoD function in serum-stimulated myoblasts (Skapek et 
al., 1995). 
It  has  been  well  established  that  the  D-type  cyclins, 
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activate the product of the retinoblastoma tumor suppres- 
sor gene, pRb (for reviews see Sherr, 1994a,b; Weinberg, 
1995).  Retinoblastoma family proteins  (i.e.,  pRb,  p107, 
and p130) are important regulators of the cell cycle (for re- 
views see  Sherr  1994a,b;  Mttller,  1995; Weinberg,  1995) 
and have been  implicated as mediators of both cellular 
growth  arrest  and  myogenic bHLH  activity in  skeletal 
muscle. The importance of this regulatory family in pro- 
moting terminal skeletal muscle differentiation was first 
suggested by the finding that expression of oncoproteins 
known to inactivate the pRb family, such as SV-40 large T 
antigen, polyoma virus  large T  antigen, and  adenovirus 
E1A, can both block differentiation and induce DNA syn- 
thesis  in  normally quiescent  myotubes  (Fogel  and  De- 
fendi, 1967; Yaffe and Gershon, 1967; Graessmann et al., 
1973; Webster et al., 1988; Endo and Nadal-Ginard, 1989; 
Enkemann et al.,  1990; Iujvidin et al.,  1990; Braun et al., 
1992; Mymryk et al., 1992; Cardoso et al., 1993; Caruso et 
al., 1993; Gu et al., 1993a; Taylor et al., 1993; Ohkubo et 
al., 1994; Crescenzi et al., 1995). Further studies have dem- 
onstrated that upon muscle differentiation, the expression 
of pRb increases (Coppola et al., 1990; Endo and Goto, 
1992; Martelli et al., 1994), and pRb assumes a hypophos- 
phorylated, activated state that is tightly tethered to the 
nucleus (Gu et al., 1993a; Thorburn et al., 1993). In addi- 
tion, DNA binding complexes containing members of the 
E2F and DP transcription factor families are found associ- 
ated with both pRb and p130 after muscle differentiation 
(Corbeil et al., 1995; Halevy et al., 1995; Kiess et al., 1995a; 
Shin et al., 1995), suggesting that both pRb and p130 may 
regulate  E2F function in  differentiated skeletal muscle. 
Furthermore, MyoD-mediated transactivation of muscle 
genes in SAOS-2 osteosarcoma cells, which lack functional 
pRb, requires coexpression of either exogenous wild-type 
pRb (Gu et al., 1993a) or p107 (Schneider et al., 1994), in- 
dicating that MyoD function may be regulated by mem- 
bers of the pRb family. Finally, pRb is required for termi- 
nal cell cycle withdrawal, as loss of pRb through targeted 
gene inactivation prevents the normal Go arrest of skeletal 
muscle (Schneider et al., 1994). 
Whereas  the  above  studies  have  suggested  that  pRb 
plays a positive role during skeletal muscle differentiation, 
mice specifically lacking Rb form grossly normal skeletal 
muscle (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 
1992, 1994), suggesting that pRb-related proteins may be 
able to compensate for the loss of pRb in the development 
of skeletal muscle. To further clarify the role of the pRb 
family in skeletal muscle differentiation, we have exam- 
ined both MyoD-mediated induction of various skeletal 
muscle proteins and MyoD-mediated cell cycle withdrawal 
in cells engineered to specifically lack either pRb, p107, or 
p130.  We have found that pRb-deficient muscle cells can 
activate normal levels of "early" differentiation markers 
(i.e., myogenin and p21);  however, expression of "late" 
differentiation markers (i.e., myosin heavy chain) is atten- 
uated in these cells, and the cells fail to exit the cell cycle. 
These differentiation defects appeared to be specific to the 
loss of pRb, as MyoD was able to fully induce the muscle 
differentiation program and promote terminal cell cycle 
arrest in the absence of either p107 or p130. 
Ectopic expression of pRb family members can signifi- 
cantly augment MyoD-mediated transactivation of a muscle 
creatine kinase--chloramphenicol acetyl transferase (MCK- 
CAT) reporter and prevent abnormal DNA synthesis in 
pRb-deficient cells, consistent with a role for this family in 
promoting the  later stages  of muscle differentiation. In 
contrast, ectopic expression of Cdk inhibitors can neither 
significantly augment MyoD function nor prevent S phase 
entry in myocytes lacking pRb, suggesting that a primary 
function of Cdk inhibitors in skeletal muscle may be  to 
maintain the hypophosphorylated, activated state of pRb. 
Finally, we demonstrate that pRb-deficient myocytes inap- 
propriately enter S phase but fail to readily progress into 
mitosis, even  though these  cells express  extremely high 
levels of cyclins A  and B, Cdk2, and Cdc2. Since caffeine 
administration,  which  removes  inhibitory  phosphoryla- 
tions on inactive Cdc2/cyclin B complexes (Steinmann et al., 
1991; Smythe and Newport,  1992),  specifically increased 
the  frequency  of  mitotic  catastrophe  in  differentiated 
pRb-deficient myocytes, we propose that the majority of 
these cells have arrested in S and G2 phases and contain 
Cdc2/cyclin B  complexes that are maintained in a  non- 
functional state by inhibitory phosphorylation. Thus, dur- 
ing the process of skeletal muscle differentiation, MyoD 
activates cell cycle-arrest mechanisms that block cell cycle 
progression in a  pRb-dependent manner in Go and in a 
pRb-independent manner in M phase. 
Materials and Methods 
Cell Culture 
Primary embryonic fibroblasts were isolated from wild-type and homozy- 
gous mutant mouse embryos at 13 d of gestation, according to the proto- 
col of Robertson (1987). Briefly, embryos were dissected and the carcass 
minced in trypsin (0.25%) for 45 min before plating in a T-75 flask. The 
adherent fibroblasts were passaged once before freezing at a density of 3 × 
106 cells per vial (Robertson, 1987). Primary embryonic fibroblast cultures 
were generally free of contaminating myoblasts and were used at passages 
3-8.  Cells were grown in DME supplemented with 10%  FBS (Hyclone 
Laboratories, Logan, VT) for primary fibroblasts or 20% FBS for C2 cells 
and fibroblast cell lines stably expressing MyoD. All cells were differenti- 
ated in DME containing 2% horse serum and 10 txg/ml insulin (differenti- 
ation medium [DM]) for 2-4 d, unless otherwise noted. 
Production of  MyoD Retrovirus 
BOSC 23 ecotropic retrovirus packaging cells (Pear et al., 1993) were gen- 
erously provided by W. Pear (Massachusetts Institute of Technology) and 
were  grown in GPT selective media (Mulligan, 1981)  until the time of 
transfection when the media was changed to DME supplemented with 
10% FBS. 2 x  106 BOSC 23 cells were seeded onto 60-mm tissue culture 
dishes in DME supplemented with 10% FBS and grown for ~24 h. The 
culture media was then replaced with 4 ml of DME supplemented with 
10% FBS and 25 IxM chloroquine just before transfection. Two plasmids 
encoding MyoD retrovirus were used, pLMDSN (Weintraub et al., 1989) 
and pBabe-MyoD, which is the  1.7-kb EcoRI  fragment containing the 
mouse MyoD gene from pVZClltx (Davis et al., 1987)  cloned into the 
EcoRI site of the vector pBabe-Puro (Morgenstern and Land, 1990).  10 
p.g of plasmid DNA was mixed with CaCI2, added dropwise to 2x Hepes 
buffered saline, pH 7.05, in a final volume of 500 p~l, and then added im- 
mediately to the above media. Cells were incubated for 8-10 h  at 37°C, 
5%  CO2, washed once with PBS, given fresh DME supplemented with 
10% FBS without chloroquine, and incubated for an additional 16 h. Me- 
dia was again removed and replaced with 3 ml of DME with 10% FBS per 
60-mm dish. Virus-containing media was harvested from the BOSC 23 
cells ~24 h later (48 h after the addition of DNA), centrifuged at 500 g to 
remove cells and debris, and then used for infection immediately or frozen 
at -80°C for later use. 
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of  Embryonic Fibroblasts 
1.5-1.75 ×  105 mouse embryonic fibroblasts (MEFs) were seeded onto 60- 
mm dishes the day before infection or-transfeetion.. In experiments where .... 
primary cultures of MEFs were transiently infected with retroviral MyoD 
and muscle gene expression was analyzed by immunoblotting, 1  ×  106 
MEFs were seeded onto 150-ram dishes. For transient viral infection, ceils 
were incubated for 24--48 h with a 1:1 mixture of virus-containing media 
from BOSC 23 cells and DME containing 20% FBS, supplemented with 
polybrene to a final concentration of 4 p,g/ml. After infection, cells were 
grown in DM for 2-4 d to induce differentiation. For the generation of sta- 
bly infected cell lines, cells were infected as described above, trypsinized, 
seeded at low culture density, and grown under selective conditions (0.4 
mg/ml G418 for pLMDSN viral infections and 1.5  p,g/ml puromycin for 
pBabe-MyoD infections) in DME supplemented with 20% FBS. Isolated 
colonies were then picked and propagated under selective growth condi- 
tions. For the time course experiments, 7.5 ×  104 Rb  -/- MEF were seeded 
into 60-ram dishes and infected the next day as described above. After 2 d, 
the viral mixture was removed and changed to DME containing 0.1% FBS 
and 10 ixg/ml insulin, and cells were maintained in this media for another 
3 d. Cultures were then stimulated with DME containing 20% FBS, and 
cells  were  fixed  at  the  indicated  time  points.  For  the  0  time  point, 
5-bromo-2'-deoxyuridine (BrdU) was added to the low-serum differentia- 
tion media and maintained on the cells for 6 h. 
For MyoD transactivation experiments, 0.5 I~g of pCSA-MyoD plasmid 
(Skapek et al., 1995) was mixed with 0,5 I~g of p-3300-MCK-CAT (Jaynes 
et  al., 1988)  or p4x(MEF1)-TK-CAT (Weintranb et  al.,  1990)  reporter 
plasmids and 1.0 Ixg of cytomegalovirus (CMV) expression vehicles en- 
coding either pRb (Qin et al., 1992), p107 (Zhu et al., 1993),  p130 (Vairo 
et aL, 1995), p16 (Skapek et al., 1995), p21  (Harper et al., 1993),  or an 
empty CMV vehicle. Plasmids were mixed in DME with 10 Ixl of lipo- 
fectamine reagent (GIBCO BRL, Gaithersburg, MD) and incubated with 
the cells for 2-3 h, according to the manufacturer's instructions. All trans- 
fections were done in duplicate. DM was added N48 h after the addition 
of DNA tothe cells, and cells were maintained under these conditions for 
an additional 2-4 d. Cells were then harvested for CAT assay, normalized 
to protein content, as previously described (Skapek et al., 1995). Transient 
transfection assays involving BrdU uptake were performed essentially as 
described above. 
Immunostaining of Converted Fibroblasts 
After differentiation, cells were washed three times with PBS, fixed in 2% 
paraformaldehyde in PBS for 15 rain, and permeabilized with 0.25% Tri- 
ton X-100 in PBS for an additional 15 rain. MyoD was then detected using 
rabbit antiserum (Tapscott et al., 1988) at a dilution of 1:250 in a blocking 
solution containing 5% goat serum, 1% horse serum, and 0.1% Triton X-100 
in PBS  and visualized using rhodamine-conjugated donkey  anti-rabbit 
IgG  antibodies  (Jackson  ImmunoResearch Laboratories,  West Grove, 
PA) at a dilution of 1:250. Myosin heavy chain (MHC) was detected using 
a  1:10  dilution  of hybridoma-conditioned media containing the mouse 
monoclonal IgG2b antibody MF-20 (kindly provided by D. Fischman, Cor- 
nell University Medical College, New York; Bader et al., 1982)  and a  1: 
250 dilution of fluoroscein-conjugated donkey anti-mouse IgG antibodies 
(Jackson ImmunoResearch Laboratories). The following additional anti- 
bodies and dilutions were used: cyclin A, a 1:500 dilution of affinity puri- 
fied rabbit antibodies (kindly provided by J. Roberts, Fred Hutchinson 
Cancer Center); cyclin B, a 1:500 dilution of affinity purified rabbit anti- 
bodies (kindly provided by C. McGowan, The Scripps Research Institute, 
La Jolla, CA), or a  1:100 dilution of commercially available affinity puri- 
fied rabbit antibodies (H-433; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA); cyclin E, a 1:1,000 dilution of rabbit antiserum (kindly provided by J. 
Roberts); Cdk2, a 1:50 dilution of affinity purified rabbit antibodies (M2; 
Santa Cruz Biotechnology, Inc.); Cdc2, a 1:200 dilution of affinity purified 
rabbit antibodies (GIBCO BRL). Stained cells were examined and photo- 
graphed using a  Zeiss Axiovert microscope (Thornwood, NY) equipped 
with a 40x water-immersion objective. 
Western Analysis 
Cells were lysed in NP-40 tysis buffer (50 mM Tris-HCl, pH 7.5,  150 mM 
NaCI, 0.5% NP-40, and 20% g~cerolwith 1 mM dithiothteitol, 1 mM phe- 
nylmethylsulfonyl  fluoride, leupeptin and pepstatin [10 p~g/ml each], apro- 
tinin [20 p.g/ml]; and phosphatase inhibitors [10 mM NaPPO4, 1 mM NaF, 
and 0.1 mM NaaVO4]  ). Cell extracts were sonicated using a Branson soni- 
cator (Branson Ultrasonics Corp., Danbury, CT), clarified by centrifuga- 
tion, and frozen at -80°C. Extracts were normalized to DNA content by 
DNA fluorometry (Hoefer Scientific Instrs., San Francisco, CA), and pro- 
teins were  separated by SDS-PAGE and transfer~,ed~-t~ nitr~ceUutose 
filters. The following antibodies and dilutions were used for immunoblot- 
ting: MyoD, a 1:500 dilution of purified monoclonal anti-MyoD antibody 
5.8A (kindly provided by P. Dias and P. Houghton, St. Jude Children's 
Research Hospital); myogenin, a  1:10 dilution of hybridoma-conditioned 
medium containing the monoclonal antimyogenin antibody F5D (kindly 
provided by W. Wright, University of Texas Southwestern Medical Cen- 
ter, Houston, TX); MHC, a  1:10 dilution of hybridoma-conditioned me- 
dium containing the monoclonal anti-MHC antibody MF20; p21, a 1:1,000 
dilution of rabbit antiserum to mouse p21 (Halevy et al., 1995);  p27, a  1: 
2,000 dilution of rabbit  antiserum to mouse p27  (kindly provided by J. 
Roberts); pRb, a 1:1,000 dilution of affinity purified monoclonal antibody 
to pRb (PMG3-245; PharMingen, San Diego, CA); p107, a 1:20 dilution of 
hybridoma-conditioned medium containing the monoclonal anti-pl07 an- 
tibody SD9 (kindly provided by N. Dyson, Massachusetts  General Hospi- 
tal Cancer Center); p130, a  1:200 dilution of affinity purified rabbit anti- 
bodies  to  p130  (C-20;  Santa  Cruz Biotechnology, Inc.),  Proteins were 
visualized using enhanced chemiluminescence (Amersham Corp., Arling- 
ton Heights, IL). 
DNA Synthesis Assay 
After differentiation, cells were  stimulated with DME containing 20% 
FBS and 10 I~M BrdU (Boehringer Mannheim Corp., Indianapolis, IN). 
Cells were washed three times with PBS, fixed for 10 rain in ice-cold AFA 
(70%  ethanol,  3.7%  formaldehyde, 5%  glacial  acetic  acid),  and  then 
washed several times more with PBS. MHC was detected using a 1:10 dilu- 
tion of the anti-MHC antibody MF-20 and a 1:250 dilution of rhodamine- 
conjugated donkey anti-mouse IgG antibodies (Jackson ImmunoResearch 
Laboratories).  After  the  secondary antibody  incubation step,  immune 
complexes were fixed for 10 rain with 2% paraformaldehyde, and DNA 
was then denatured by incubation of the ceils in 2 N HCI, 0.2% Triton X-100 
for 10 min. Cells were washed with PBS, incubated with 50 mM glycine in 
PBS for 5 rain, and washed again with PBS. BrdU was detected using ei- 
ther a  1:30 dilution of a  FITC-conjugated monoclonal antibody against 
BrdU or a 1:2,000 dilution of a mouse monoclonal IgGl antibody to BrdU 
(G3G4) and a 1:200 dilution of biotinylated-goat anti-mouse IgGl-specific 
antibodies (Southern Biotechnology Associates, Inc. Birmingham, AL) 
followed by incubation with a 1:250 dilution of fluorescently labeled avi- 
din D  (Vector Laboratories, Inc., Burlingame, CA) and I  ~g/ml 4', 6'-dia- 
midino-2-phenylindole (DAPI) in PBS. 
Flow Cytometry 
Myogenic cell lines were differentiated for 2-3 d in low-calcium differenti- 
ation medium consisting of CaCl2-free DME  (GIBCO  BRL)  reconsti- 
tuted with CaC12 to a final concentration of 50 ~M and supplemented with 
2% dialyzed horse serum and 10 p,g/ml insulin. Under these culture condi- 
tions, N98%  of C2 muscle cells expressing MHC remained mononucle- 
ated. Cultures were then trypsinized and resuspended in PBS containing 
1% horse serum, centrifuged at 800 g for 5 rain at 4°C, and washed several 
times with PBS. Ceils were fixed in PBS containing 2% paraformaldehyde 
for 15 min on ice, incubated with 50 mM glycine for an additional 5 rain, 
permeabilized in 0.1% Triton X-100 in PBS for 15 min, washed several 
times with PBS, and then stained for MHC as described above. After anti- 
body staining, cell pellets were resuspended in a propidium iodide solu- 
tion (69 I~M propidium iodide, 38 mM sodium citrate) to a concentration 
of approximately 1 ×  106 cells/ml, RNase A was added to a final concen- 
tration of 10 I~g/ml, and samples were incubated for 30 min at 37°C. Cells 
were then examined for fluoroscein and propidium iodide fluorescence 
using a Becton-Dickinson FACScan  ® flow cytometer (Becton-Dickinson 
Immunocytometry Sys., Mountain View, CA) and analyzed using Lysis II 
and CellFit software (Becton-Dickinson Immunocytometry Sys.). Negative 
controls included nonmyogenie cell lines and primary embryonic fibro- 
blasts processed as described above and myogenic cell lines stained with 
the secondary antibodies alone. 
Caffeine Treatment 
Established myogenic cell lines were serum-starved for 3 d in DME con- 
taining 0.1% FBS plus 10 ~g/ml insulin. Cells were then stimulated with 
high-serum  medium (DME containing 20% FBS) for 12 h and then grown 
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DME containing 20% FBS. Ceils were fixed  in 2% paraformaldehyde in 
PBS and stained for MHC and DAPI as described above, 
Results 
pRb Is Necessary for High-Level Expression of a Subset 
of Muscle Genes 
To examine the requirement of pRb family members for 
skeletal muscle differentiation, we infected primary MEFs 
obtained from wild-type mouse embryos (WT) or embryos 
lacking both copies of either the Rb gene (Rb-/-; Jacks 
et al.,  1992),  the p107 gene (p107-/-),  or the p130 gene 
(p130-/-),  with a retrovirus encoding MyoD. After infec- 
tion, the cells were challenged to differentiate by serum re- 
moval, and both MyoD expression and muscle differentia- 
tion in  the  various infected fibroblast populations were 
examined by immunocytochemistry.  Ectopic expression of 
MyoD induced expression of MHC in each of the fibro- 
blast genotypes tested (Fig. 1). However, we consistently 
observed intense MHC staining with wild-type, p107 -/-, 
and p130 -/- fibroblasts (Fig. 1, B, H, and K) and relatively 
weak MHC staining in cells lacking pRb (Fig. 1 E), even 
though the expression levels of MyoD were comparable in 
these cell populations (Fig. 1 A, D, G, and J). In addition, 
the resultant pRb-deficient myocytes formed smaller myo- 
tubes that predominantly contained one or two nuclei in 
comparison with wild-type, p107 -/-, or p130 -/- myocytes, 
which frequently contained several nuclei, suggesting that 
myocyte  fusion may also be impaired in the absence of pRb. 
To better characterize the defects in pRb-deficient myo- 
cytes,  we  generated  cell  lines  stably expressing  MyoD. 
Western analysis of a representative cell line lacking pRb 
(Rb-/--MyoD) demonstrated that MyoD protein accumu- 
lated to high levels in these cells and could induce expres- 
sion of myogenin, an early marker of the muscle differenti- 
ation program (Hollenberg et al., 1993; Andr6s and Walsh, 
1996),  to  a  level  comparable  to  that  in  a  pRb-positive 
10T1/2  fibroblast  cell  line  expressing  retroviral  MyoD 
(10T1/2-MyoD)  (Fig. 2 A, compare lanes 2  and 4).  The 
Cdk inhibitor p21,  another early marker of the skeletal 
muscle differentiation program (Guo et al., 1995; Halevy 
et al., 1995; Missero et al., 1995; Parker et al., 1995; Andr6s 
and Walsh, 1996), was similarly induced to wild-type levels 
in the absence of pRb (Fig. 2 A). In contrast to the normal 
levels of expression of these early markers of muscle dif- 
ferentiation, expression of MHC, which is induced at rela- 
tively late times in the skeletal muscle differentiation pro- 
gram (Gunning et al.,  1987; Lin et al.,  1994; Andr6s and 
Walsh, 1996; see also Ohkubo et al., 1994), was dramati- 
cally reduced in cells lacking pRb (Figs. 1 and 2). To con- 
firm that these findings were not specific to these individual 
cell  lines,  we  transiently infected  both  WT and  Rb -/- 
MEFs with a MyoD retrovirus and analyzed the relative 
expression  levels  of  muscle  differentiation markers  in 
these polyclonal populations. MyoD activated the expres- 
sion of both myogenin and p21 in pRb-deficient MEFs to 
levels that were  equal to or even greater than that ob- 
served in WT MEFs, but failed to induce high level MHC 
expression specifically in the pRb-deficient cells (Fig. 2 B). 
Together, these findings indicate that while pRb is not es- 
sential for either the initiation of the skeletal muscle dif- 
ferentiation program or the induction of early muscle pro- 
teins  such  as  myogenin and  p21,  pRb  is  necessary  to 
promote high-level expression of some end-stage differen- 
tiated muscle proteins such as MHC. 
Since the pRb-related proteins p107 and p130 may also 
be involved in the regulation of muscle differentiation, we 
examined the expression of these proteins in myogenic cell 
lines that either contained or lacked pRb. In pRb-positive 
10T1/2-MyoD cells, p107  protein levels appeared  to de- 
cline  slightly  under  differentiation conditions,  whereas 
p107  increased in  the comparable pRb-deficient muscle 
cell line (Fig. 2 A; see also Schneider et al., 1994). Consis- 
tent with its increased presence in E2F complexes in dif- 
ferentiated muscle cells (Corbeil et al., 1995; Halevy et al., 
1995; Kiess et al., 1995a; Shin et al., 1995),  total protein 
levels of p130 increased upon serum starvation in both the 
pRb-positive  and  -negative  muscle  cell  lines  (Fig.  2 A, 
compare lanes 1 and 2; lanes 3 and 4). However, we also 
observed an increase in p107 and p130 expression in pRb- 
deficient fibroblasts that lacked MyoD expression (data 
not shown), suggesting that the increases in p107 and p130 
protein are not specific to muscle differentiation. In sum- 
mary, although p107 and p130 levels are increased in pRb- 
deficient muscle cell cultures, the reduced MHC expres- 
sion in these cells indicates a specific role for pRb in the 
regulation of the myogenic differentiation program. 
pRb Family Proteins but Not Cdk Inhibitors Augment 
the Activity of MyoD 
As an independent means of evaluating the requirement 
of pRb for MyoD function, we transiently cotransfected 
pRb-deficient MEFs with plasmids encoding MyoD under 
the  control  of  the  cytomegalovirus  promoter  (CMV- 
MyoD) and a reporter construct containing the regulatory 
sequences of the muscle creatine kinase gene driving ex- 
pression  of  chloramphenicol  acetyl  transferase  (MCK- 
CAT).  When  transfected into pRb-deficient fibroblasts, 
CMV-MyoD did not significantly activate expression of 
MCK-CAT (Fig. 3 A, lane 3), even when coexpressed with 
CMV-driven E12, a bHLH binding partner of MyoD (Fig. 
3 A, lane 4). In contrast, expression of MCK-CAT was in- 
creased 23-35-fold when a pRb expression vehicle (CMV- 
pRb)  was cotransfected with MyoD and E12  (Fig. 3 A, 
lane 5).  In the  absence  of MyoD, pRb did not activate 
MCK-CAT expression in these cells (data not shown). 
MCK gene  expression requires  binding sites  for both 
myogenic  bHLH  proteins  and  MEF2  family members 
(Cserjesi and Olson,  1991; Amacher et al.,  1993); there- 
fore, it was unclear from these results whether pRb was af- 
fecting the function of MyoD or other ancillary transcrip- 
tion  factors  such  as  MEF2.  To  ascertain  whether  pRb 
directly affected the activity of MyoD, we assayed the abil- 
ity of MyoD to induce the expression of a simplified mus- 
cle  reporter  construct containing four reiterated  MyoD 
binding sites (MEF1 sites) upstream of a minimal thymi- 
dine kinase promoter driving CAT (4x [MEF1]-TK-CAT) 
in pRb-deficient cells (Fig. 3 A). In either the absence or 
presence  of ectopic E  protein,  MyoD activated this re- 
porter poorly in cells lacking pRb (Fig. 3 A, lanes 8 and 9). 
However, cotransfection of MyoD and E12  with CMV- 
The Journal of Cell Biology, Volume 135, 1996  444 Figure 1.  Attenuated expression of myosin heavy chain in differentiated  myocytes lacking pRb. MEFs were infected with an ecotropic 
retrovirus encoding MyoD driven by a constitutive viral promoter and then differentiated for 3 d. After differentiation, cells were fixed, 
permeabilized,  and immunostained  for MyoD (A, D, G, and J) and MHC (B, E, H, and K). Nuclei were visualized by staining with 
DAPI (C, F, I, and L). 
pRb  led to a  3-10-fold increase in  4x(MEF1)-TK-CAT 
expression in Rb -/- cells (Fig. 3 A, lane 10). Since cotrans- 
fected  CMV-pRb  only slightly enhanced  the  activity of 
CMV-CAT (approximately twofold; data not shown) and 
does not greatly affect MyoD protein levels (Skapek, S., 
and A,B. Lassar, data not shown), the dependency on ec- 
topic pRb to promote high-level gene expression in Rb -l- 
cells appears to be specific to MCK-CAT, 4x(MEF1)-TK- 
CAT and other muscle-specific reporter constructs (data 
not shown). At present, it is unclear why pRb augments 
expression of all  transfected muscle  reporter constructs 
yet is required for high level expression of only late mark- 
ers of the endogenous muscle differentiation program. 
Because p107 and p130 have several biochemical prop- 
erties in common with pRb (for reviews see Mtiller, 1995; 
Vairo et al., 1995; Weinberg, 1995; Zalvide and DeCaprio, 
1995), we tested whether higher-level expression of these 
proteins  could  substitute  for  pRb  in  supporting  MyoD 
function. Both CMV-driven p107 and p130 were able to 
augment MyoD-mediated transactivation of MCK-CAT, 
although in both cases the level of MCK-CAT expression 
was  significantly below that  observed following cotrans- 
fection with CMV-pRb (Fig. 3 B, compare lanes 4 and 5 
with lane 3).  Since ectopic expression of Cdk  inhibitors 
can promote MyoD function in pRb-positive C2 myoblasts 
and pRb-positive 10T1/2 fibroblasts (Skapek et al., 1995), 
we evaluated whether reduction of Cdk activity could in- 
crease MyoD activity in the absence of pRb. In pRb-defi- 
cient cells, neither cotransfection of CMV-driven p16 nor 
CMV-p21  significantly augmented MyoD transactivation 
of MCK-CAT; however, in the presence of ectopic pRb, 
cotransfection with  either Cdk  inhibitor boosted  MyoD 
function in these cells (Fig. 3 C). Together, these data indi- 
cate that MyoD-mediated transactivation of muscle pro- 
Novitch et al. pRb in Myogenesis  445 Figure 2.  Differential expression of early versus late differentia- 
tion markers in pRb-deficient myocytes. (A) pRb-positive 10T1/2 
fibroblasts and Rb -I- MEFs were stably infected with a retrovi- 
rus encoding MyoD driven by a constitutive viral promoter. Pro- 
tein lysates were then made from cultures that were either expo- 
nentially  growing  (G)  or  differentiated  for 3  d  (D).  Lysates, 
normalized  to  DNA  content, were  subjected  to  SDS-PAGE, 
transferred to nitrocellulose, and immunoblotted  with the indi- 
cated antibodies.  (B) WT and Rb -/- MEFs were transiently  in- 
fected with a MyoD retrovirus, allowed to differentiate, and sub- 
jected to immunoblotting analysis as in A. 
moters is compromised in cells lacking pRb. Overexpres- 
sion of p107 and p130 can partially restore MyoD activity, 
raising the possibility that a critical mass of any member of 
the pRb family may be sufficient to ensure normal muscle 
differentiation;  nevertheless,  the  endogenous  levels  of 
p107 and p130 fail to compensate for the loss of pRb. Fi- 
nally, the enhancement of MyoD activity by p16 and p21 is 
dependent on the presence of pRb, supporting a role for 
these  proteins  in  maintaining  the  functional, hypophos- 
phorylated state of pRb in differentiated skeletal muscle. 
pRb Alone Is Necessary for Permanent Growth Arrest 
Previous studies  have demonstrated that infection of al- 
ready differentiated skeletal  muscle  cultures  with  DNA 
tumor viruses, or induction of the SV-40 large T  antigen 
within myotubes, can induce DNA synthesis and mitosis 
(Fogel  and  Defendi,  1967;  Yaffe  and  Gershon,  1967; 
Graessmann  et al.,  1973;  Endo and Nadal-Ginard,  1989; 
Iujvidin et al., 1990; Cardoso et al.,  1993; Gu et al., 1993a; 
Ohkubo et al., 1994; Crescenzi et al., 1995). Since viral on- 
coproteins inactivate the entire pRb family, induce the ex- 
pression of c-jun, Cdks, and cyclins (Endo, 1992; Ohkubo 
et al.,  1994),  and  extinguish expression of the myogenic 
bHLH factors (Endo, 1992), it was unclear whether all or 
only a subset of these induced cellular responses was nec- 
essary  to  permit  DNA  synthesis  in  differentiated myo- 
cytes. To specifically examine the role of pRb family mem- 
bers in this process, wild-type (WT), Rb -/-, p107  -/-, and 
p130  -/- MEFs were transiently infected with a retrovirus 
encoding  MyoD  and  challenged  to  differentiate  under 
low-serum conditions. After 2 d of differentiation, the cells 
were refed with medium containing both high serum (i.e., 
20%  FBS)  and  the  thymidine analogue  BrdU  and  then 
fixed 36 h later for evaluation of BrdU uptake. Differenti- 
ated, MHC-expressing myocytes containing pRb failed to 
synthesize DNA after serum stimulation, as evidenced by 
the  absence  of BrdU  incorporation in  these  cells,  even 
when the cells lacked either p107 or p130 (Fig. 4, A, C, and 
D).  In  marked  contrast,  75--85%  of  the  pRb-deficient, 
MHC-positive myocytes had incorporated BrdU after 36 h 
in high-serum media (examples are displayed in Fig. 4 B). 
These  results  are  consistent  with  the  findings  of others 
(Schneider et al., 1994)  and indicate that pRb alone is re- 
quired to inhibit DNA synthesis and maintain Go arrest in 
differentiated myocytes. 
We next evaluated whether ectopic expression of other 
pRb family members or Cdk inhibitors could restore ter- 
minal G O  arrest to pRb-deficient myocytes. MEF cultures 
were transiently cotransfected with CMV-MyoD  and ei- 
ther  CMV-driven  pRb,  p107,  p130,  p16,  or  p21.  After 
transfection, the cells were induced to differentiate in low- 
serum medium for 2 d  and then stimulated with medium 
containing 20%  FBS supplemented  with  BrdU  (Fig.  5). 
Expression of exogenous pRb, p107, p130,  and p21  was 
confirmed by immunostaining dishes transfected in paral- 
lel (data  not  shown).  Under  these  conditions, N82%  of 
pRb-deficient MHC-positive  cells cotransfected with  an 
empty  CMV  expression  vehicle  incorporated  BrdU. 
Cotransfection of CMV-MyoD  with  CMV-pRb  reduced 
BrdU uptake to ~5% in MHC-positive cells (Fig. 5, lane 2). 
Cotransfection of CMV-MyoD with CMV-pl07 or CMV- 
p130 also reduced BrdU uptake in MHC-positive cells, in 
these cases to ~22 and 42%, respectively (Fig. 5, lanes 3 
and 4). In contrast to the reduction in BrdU incorporation 
after cotransfection of MyoD with pRb family members, 
cotransfection with either p16 or p21 failed to significantly 
prevent DNA synthesis in pRb-deficient myocytes (Fig. 5, 
lanes 5  and 6). Together, these results demonstrate  that 
ectopic expression of any pRb family member can main- 
tain  the  Go arrest of skeletal muscle to some  extent. In 
contrast, neither endogenous levels of the Cdk inhibitors 
p21 and p27 (Fig. 2), nor ectopic p16 or p21 (Fig. 5) are ca- 
pable of preventing S phase entry in differentiated myo- 
cytes in the absence of pRb. 
pRb-deficient Myocytes Accumulate in S and G2 Phases 
Having established that pRb-deficient differentiated myo- 
cytes display aberrant BrdU incorporation, we examined 
the DNA content of these cells to verify that incorporation 
of BrdU signified entry into S phase versus DNA repair. 
To monitor DNA content, we performed flow cytometry on 
cultures of myocytes that either contained or lacked pRb 
and quantitated the amount of propidium iodide fluores- 
cence in either MHC-positive or -negative cells in the pop- 
ulation. During the process of skeletal muscle differentiation, 
normal, pRb-containing myocytes fuse to form multinucleate 
myotubes.  Thus,  we  could  not  easily  evaluate  nuclear 
DNA content in whole cells under normal differentiation 
conditions  because  of multinucleation  of myotubes.  To 
minimize  this  problem,  we  used  culture  conditions  in 
which muscle differentiation and terminal cell cycle arrest 
could occur in the absence of cell fusion, based on the sen- 
sitivity of fusion to the concentration of calcium in the 
media (for example see Adamo et al.,  1973).  Under low- 
calcium differentiation conditions  (50  IxM  CaCl2),  pRb- 
positive 10T1/2-MyoD cells failed to form multinucleated 
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Figure 3.  MyoD transactiva- 
tion  of  exogenous  muscle 
genes  requires  pRb  family 
members.  (A)  Effects  of 
CMV-pRb  on  CMV-MyoD 
transactivation  of  a  MCK- 
CAT  reporter  construct 
(lanes  1-5, filled bars),  or a 
simplified muscle-specific re- 
porter containing four reiter- 
ated MyoD binding sites up- 
stream  of  a  minimal 
thymidine  kinase  promoter 
driving  the  CAT  gene  (4× 
[MEF1]-CAT)  (lanes  6--10, 
open  bars),  pRb-deficient 
MEFs  were  cotransfected 
with CMV-MyoD (lanes 3-5; 
8-10), CMV-E12  (lanes 2, 4, 
5,  7, 9,  and 10),  and  CMV- 
pRb (lanes  5  and IO).  CAT 
activity  relative  to  lanes  5 
and 10 are displayed, respec- 
tively.  Error  bars  represent 
duplicate  plates from a rep- 
resentative  experiment.  (B) 
Augmentation of MCK-CAT 
expression  in  pRb-deficient 
fibroblasts  after  cotransfec- 
tion  of  CMV-MyoD  (lanes 
2-5) with CMV-pRb (lane 3), 
p107 (lane 4), and p130 (lane 
5).  CAT activity  relative to 
lane  3 is displayed.  (C) En- 
hancement of MyoD activity 
by  Cdk  inhibitors  requires 
the presence of cotransfected 
pRb.  pRb-deficient  fibro- 
blasts  were  cotransfected 
with CMV-MyoD (lanes 1-5), 
CMV-pRb  (lanes  3-5), 
CMV-pl6  (lanes  1  and  4), 
and  CMV-p21  (lanes  2  and 
5).  CAT activity  relative  to 
lane 3 is displayed. 
myotubes,  and  the  majority  of  the  MHC-positive  cells 
(~86%) had accumulated in GJG0, as measured by pro- 
pidium iodide fluorescence (Fig. 6 A). In these pRb-con- 
taining cells, the frequency of cells with an S phase DNA 
content was reduced to 3% in the MHC-positive portion 
of the population compared to 17% in the MHC-negative 
portion, while the proportion of cells with a G2+M DNA 
content  was the same (11%)  in  both portions  (Fig.  6, A 
and B). Identical results were seen with pRb-positive C2 
muscle cells (data not shown). In pRb-deficient cells, the 
frequency of MHC-positive cells with  an  S  phase DNA 
content  was 20%  and  that  with  a  G2+M DNA content 
was 24%. In contrast, only 12 and 13% of the MHC-nega- 
tive cells in this population displayed either an S or G2+M 
DNA  content,  respectively  (Fig.  6,  C  and  D).  Thus, 
whereas differentiated  pRb-positive myocytes or nondif- 
ferentiated pRb-deficient cells maintain predominantly a 
2 N DNA content in low serum conditions, pRb-deficient 
myocytes display a relative tendency to accumulate a  >2 
N DNA content under identical conditions, 
Interestingly, a  number of MHC-positive cells lacking 
pRb appeared to have a  >4 N  DNA content, suggesting 
that these cells had undergone  multiple rounds  of DNA 
replication  after  differentiation.  Indeed,  pRb-deficient 
myocytes frequently  had  enlarged  nuclei  with  increased 
DAPI fluorescence (data not shown). To exclude the pos- 
sibility that incubation specifically under low-calcium dif- 
ferentiation conditions  was altering the DNA content of 
pRb-deficient myocytes, we repeated  our analysis under 
normal-calcium  differentiation  conditions  and  analyzed 
DNA content in individual nuclei isolated from differenti- 
ated myotubes by performing flow cytometric analysis us- 
Novitch et al. pRb in Myogenesis  447 Figure 4.  pRb is required to inhibit DNA synthesis in differentiated myocytes. WT (A), Rb  -/- (B),pl07  -/- (C), andp130  -/- (D) MEFs 
were infected with a MyoD retrovirus, differentiated, and then incubated in media containing 20% FBS and 10 I~M BrdU for 36 h. Cells 
were then fixed, permeabilized, and stained for MHC (red) and BrdU (green). Note the specific uptake of BrdU in the nuclei of the Rb  -/- 
MHC-positive cells (B). 
ing myogenin as  a  nuclear  differentiation marker.  With 
this  approach, we found that  69%  of myogenin-positive 
nuclei isolated from the pRb-deficient myocytes had a >2 
N DNA content (as compared to 28% in the nondifferen- 
tiated cells in this population) and that a significant por- 
tion of these differentiated nuclei had a >4 N DNA content, 
although in this case nuclear clumping prevented a thorough 
statistical evaluation of this phenomenon (data not shown). 
pRb-deficient Myocytes Enter S Phase but Do Not 
Readily Progress to Mitosis 
To examine the kinetics of cell cycle progression in pRb- 
deficient myocytes, we infected pRb-deficient MEFs with 
a MyoD retrovirus, induced the cells to differentiate in mi- 
togen-poor medium for 3 d, and followed progression of 
these cells through the cell cycle following serum stimula- 
tion (Fig. 7). Under low-mitogen conditions, nearly 50% 
of the cells incorporated BrdU into their nuclei during the 
last 6 h of culture in this medium, regardless of MHC ex- 
pression,  demonstrating  the  low  serum  requirement  of 
MEFs  lacking pRb  (Fig.  7  A).  After serum  stimulation, 
75%  of MHC-negative  cells  in  the  population  incorpo- 
rated BrdU by 12 h, and nearly all of the MHC-negative 
cells took up BrdU by 24 h. In contrast, the percent of the 
MHC-positive cells incorporating BrdU did not increase 
above the 50% base line during the first 12 h after serum 
stimulation,  and  this  frequency only slowly increased to 
~70%  after 48 h. These data indicate a kinetic difference 
in cell cycle reentry after serum stimulation, with MHC- 
expressing cells entering S phase at a slower rate than their 
MHC-negative counterparts. 
As a marker for the G1 to S transition, we also examined 
the expression of cyclin A, which normally peaks during 
this stage of the cell cycle and likely participates in S phase 
entry and progression (Pagano et al., 1992). Cyclin A  ex- 
pression was observed in 22% of the MHC-negative cells 
maintained in low-serum conditions, and this frequency of 
expression slightly increased following serum stimulation 
to a peak of 35% after 24 h  (Fig. 7 B). In contrast to the 
low  level and  frequency of cyclin A  expression in  cells 
lacking MHC staining, cyclin A protein, which is normally 
absent in  MHC-positive myocytes containing pRb  (data 
not shown; see also Ohkubo et al., 1994; Rao et al.,  1994; 
Guo et al., 1995), was present in 67% of the MHC-positive 
cells maintained in the low-serum conditions, and the in- 
tensity of staining  was  dramatically enhanced  over that 
seen in MHC-negative cells (Fig. 8 A-C). 48 h after serum 
stimulation, the percentage of MHC-positive cells express- 
ing high levels of cyclin A  steadily declined to 55%. We 
also evaluated the expression of cyclin E  and Cdk2, which 
are normally present in MHC-positive myocytes contain- 
ing pRb (data not shown; see also Jahn et al., 1994; Guo et 
al., 1995; Kiess et al., 1995b), and found that these proteins 
were also elevated in MHC-expressing myocytes lacking 
pRb (Fig. 8, G-l, J-L). These findings suggest that up to 
50%  of  pRb-deficient,  MHC-positive  myocytes  are  al- 
ready in S phase while maintained under low serum condi- 
tions,  and  that  mitogen stimulation  can induce an  addi- 
tional percentage of these cells to progress into S phase 
with kinetics that are slow compared to the MHC-negative 
cells in the population. 
To evaluate further progression of pRb-deficient myo- 
cytes through the cell cycle, we monitored the expression 
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Figure 5.  Suppression  of BrdU  uptake in  differentiated pRb- 
deficient myocytes by pRb family members, but not by Cdk in- 
hibitors. Rb -/- fibroblasts were cotransfected  with CMV-MyoD 
and either an empty CMV expression vehicle (lane 1), CMV-pRb 
(lane  2),  CMV-pl07  (lane  3),  CMV-pl30  (lane  4),  CMV-pl6 
(lane 5), or CMV-p21 (lane 6). Ceils were differentiated  for 2 d 
under low-serum conditions, stimulated with high-serum media 
containing 10 I~M BrdU for 24-48 h, fixed, and immunostained 
for both MHC and BrdU. The displayed results are the average 
percentage of MHC-positive  cells that incorporated BrdU de- 
rived from five independent experiments. Error bars depict varia- 
tion between  the experiments. The total number of MHC-posi- 
tive  cells counted for each plasmid  combination  were:  empty 
CMV vehicle (n = 959), CMV-pRb (n = 1118), CMV-pl07 (n --- 
836), CMV-pl30  (n = 361), CMV-pl6  (n = 528), and CMV-p21 
(n = 530). 
of cyclin B in these cells as a marker for the GJM transi- 
tion. Cyclin B  normally accumulates in the cytoplasm of 
proliferating cells during S and G2 and then translocates to 
the nucleus just before mitosis (Pines and Hunter, 1991). 
Surprisingly, cyclin B protein, which is absent from pRb- 
containing myocytes (data not shown; see also Ohkubo et al., 
1994; Rao et al., 1994), accumulated in the nuclei of differ- 
entiated pRb-deficient myocytes (Fig. 8, D-F) and was ob- 
served in 17% of the MHC-positive cells under low-mito- 
gen conditions. This frequency steadily increased to N25 % 
after serum stimulation (Fig. 7 C), suggesting that a subset 
of pRb-deficient myocytes are capable of reaching the ear- 
liest stages of mitosis. In contrast, cyclin B  expression in 
the  MHC-negative  population  slightly  increased  during 
the first  12 h  of serum  stimulation  (Fig. 7  C),  and then 
sharply declined by 24 h, coinciding with a peak in mitosis 
(Fig.  7  D).  Whereas  a  wave  of mitosis  occurred in  the 
MHC-negative cells in the population at 24 h after serum 
stimulation,  mitosis was  not evident in MHC-expressing 
cells until the latest time point (48 h after serum addition), 
where a very small number of MHC-positive cells in mito- 
sis was noted (Fig. 7 D). Together, the absence of a decline 
in cyclin B  levels and relative infrequency of mitoses in 
pRb-deficient myocytes suggest that these cells can traverse 
S phase and enter G2 but fail to fully progress into mitosis. 
pRb-deficient Myocytes Express Both Cdc2 and 
Cyclin B and Can Be Driven into Mitosis Prematurely 
by Caffeine Treatment 
To clarify the mechanism of the apparent mitotic blockade 
in  pRb-deficient myocytes, we  examined whether Cdc2, 
the  catalytic partner  for cyclin B,  was  present  in  these 
cells. Interestingly, Cdc2 was specifically elevated in dif- 
ferentiated pRb-deficient myocytes as visualized by immu- 
nostaining (Fig. 8, M-O) and absent from pRb-containing 
muscle cells cultured in parallel (data not shown; see also 
Cardoso et al., 1993; Jahn et al., 1994; Ohkubo et al., 1994; 
Rao et al., 1994; Guo et al., 1995; Wang and Nadal-Ginard 
1995). Since both Cdc2 and cyclin B were expressed at ex- 
tremely high levels in at least a fraction of pRb-deficient 
myocytes,  it  seemed  paradoxical  that  the  mitotic  fre- 
quency was quite low in these cells. We reasoned that the 
absence of mitosis could result from a failure to activate 
the Cdc2/cyclin B complex. This complex is negatively reg- 
ulated by inhibitory phosphorylations on Cdc2 at threo- 
nine 14  and tyrosine 15, thought to be mediated  by the 
weel/mikl  kinase family, and positively regulated by the 
removal of these inhibitory phosphorylations bY the cdc25 
phosphatase  family (for reviews see  Coleman  and Dun- 
phy, 1994; King et al., 1994). 
As MHC-expressing cells constitute only a  small frac- 
tion of cells in pRb-deficient myogenic cell cultures, we 
were unable  to biochemically evaluate the phosphoryla- 
tion status of Cdc2 specifically in the MHC-positive por- 
tion of the population. To address whether Cdc2 accumu- 
lated in an inactive, phosphorylated form in pRb-deficient 
myocytes, we examined the effects of caffeine administra- 
tion on these cells. Caffeine treatment has previously been 
shown to trigger premature mitosis (i.e., "mitotic catastro- 
phe") in S phase-arrested cells containing Cdc2/cyclin B 
complexes (Schlegel and Pardee,  1986; Steinmann et al., 
1991)  by  removing  the  inhibitory  phosphorylations  on 
Cdc2 (Steinmann et al., 1991; Smythe and Newport, 1992). 
Thus, cells containing incompletely replicated DNA and 
expressing both Cdc2 and cyclin B should display aberrant 
mitosis  (i.e., mitotic catastrophe) in response to caffeine 
administration,  pRb-deficient myocytes were induced to 
differentiate  under  low-mitogen  conditions,  stimulated 
with  high  levels  of  serum  for  12  h,  and  subsequently 
treated with 5 mM caffeine. The frequency of normal and 
abnormal mitoses was then quantitated 6 h after caffeine 
administration in both cells containing and lacking MHC 
expression.  Caffeine  treatment  of  the  MHC-expressing 
cells led to a 10-fold increase in the frequency of abnormal 
mitoses, characterized by a  "pulverized" nuclear appear- 
ance (Fig. 9, compare B  and D). This pulverized nuclear 
phenotype  is  reminiscent of the  mitotic  catastrophe  in- 
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Figure  6.  Differentiated 
pRb-deficient  myocytes  ac- 
cumulate  an  S  or  Gz+M 
phase  DNA  content,  pRb- 
positive  10T1/2-MyoD cells 
(A  and  B)  and  a pRb-defi- 
cient cell line stably infected 
with MyoD retrovirus (Rb  -/-- 
MyoD) (C and D) were dif- 
ferentiated for 3 d in media 
containing  low  amounts  of 
calcium  to  inhibit  myocyte 
fusion. Whole cells were de- 
tached from dishes, washed, 
fixed, stained  for MHC (us- 
ing a monoclonal antibody to 
MHC) and  for DNA (using 
propidium  iodide),  and ana- 
lyzed  using  flow cytometry. 
The DNA content of MHC- 
positive cells (A and C) and 
MHC-negative  cells (B  and 
D) are shown. 
duced by overexpression of the Cdc2 activator cdc25 in the 
presence of both Cdc2 and cyclin B  (Heald et al., 1993) 
and was only observed in the MHC-positive cells in the 
population (summarized in Table I). In contrast to the in- 
creased frequency of pulverized nuclei in MHC-expressing 
cells, caffeine treatment only modestly increased the fre- 
quency of normal mitosis in the MHC-positive cells from 
~0.8 to 1.2% and had little effect on the number of normal 
mitosis in MHC-negative cells (Table I). The effects of caf- 
feine were also specific to myocytes lacking pRb and did 
not alter the nuclear morphology of pRb-containing mus- 
cle cells cultured in parallel (data not shown). In summary, 
these experiments indicate that caffeine treatment specifi- 
cally increases the frequency of mitotic catastrophe in dif- 
ferentiated pRb-deficient myocytes, consistent with an ar- 
rest of these cells in S and G2 phases with an accumulation 
of Cdc2/cyclin B complexes that are maintained in a non- 
functional state by inhibitory phosphorylation. 
Discussion 
It has been very well documented that DNA tumor viruses 
such as SV-40, polyoma, and adenovirus can inhibit differ- 
entiation and reactivate the mitotic cell cycle in already 
formed  myotubes.  Several studies  have  further  demon- 
strated that the oncoproteins harbored in these viruses are 
alone  capable  of blocking  differentiation  and  initiating 
DNA synthesis. However, interpretation of these studies 
has been complicated, since these  viral oncoproteins se- 
quester numerous proteins (including the pRb family, the 
p300 family, and p53; Moran, 1993), induce cell cycle regu- 
lators (Endo, 1992; Ohkubo et al., 1994), and extinguish 
myogenic bHLH gene  expression  (Endo,  1992).  In  this 
study, we have analyzed the role of pRb family proteins in 
muscle  gene  activation  and  in  terminal  cell cycle with- 
drawal, In agreement with the results of Nadal-Ginard and 
colleagues who examined muscle differentiation in an ES 
cell-derived myogenic cell line lacking pRb (Schneider et al., 
1994) and with analysis of pRb-deficient mice that develop 
a grossly normal musculature (Clarke et al., 1992; Jacks et 
al., 1992; Lee et al., 1992, 1994), we have observed that at 
least some aspects of skeletal muscle differentiation can 
proceed in the absence of pRb (summarized in Fig. 10). 
pRb Is Necessary  for High-Level 
Expression of  Late Markers of the Skeletal Muscle 
Differentiation Program 
Whereas pRb-deficient myocytes express normal levels of 
early  muscle  differentiation markers  such  as  myogenin 
and p21, high-level expression of genes activated in the 
end stages  of muscle  differentiation, such  as  MHC  and 
MCK, apparently require pRb. These findings are consis- 
tent with the observation that inhibition of C2 myoblast 
differentiation by SV-40 T  antigen apparently occurs at a 
step after the induction of myogenin (Tedesco et al., 1995). 
Once  the  muscle  differentiation program is  triggered, a 
positive feedback loop is established as MyoD induces the 
Cdk inhibitor p21  (Guo et al., 1995; Halevy et al., 1995; 
Missero et al., 1995; Parker et al.,  1995). This may prima- 
rily serve to ensure that pRb maintains its active, hypo- 
phosphorylated state, which is critical for later stages of 
differentiation. Indeed, cotransfection of both p16 and p21 
can augment MyoD function only in the presence of pRb. 
Other Cdk inhibitors that increase upon muscle differenti- 
ation, such as p27 (Halevy et al., 1995), or that are highly 
expressed in  differentiated skeletal muscle,  such  as  p18 
(Guan et al., 1994) and p57 (Lee et al., 1995; Matsuoka 
et al.~ 1995), may also contribute to this process. 
Although  pRb-deficient myocytes express  other  pRb 
family members (i.e., p107 and p130), the endogenous lev- 
els of these pRb-related proteins are apparently unable to 
compensate for the loss of pRb in promoting MHC ex- 
pression. Indeed, a unique role for pRb in allowing high- 
level expression of late muscle differentiation markers is 
consistent with the finding that MyoD activates apparently 
normal levels of MHC expression in MEFs engineered to 
specifically lack either p107 or p130 but induces signifi- 
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Figure  7.  Differentiated  pRb-deficient  myocytes  display  a  de- 
layed entry into S phase  after growth factor stimulation and do 
not readily progress into mitosis. Rb -/- MEFs were infected with 
a retrovirus containing MyoD and differentiated for 3 d in media 
containing 0.1% FBS plus 10 txg/ml insulin. After differentiation, 
cultures were stimulated with media containing 20% FBS, fixed 
cantly decreased levels of this late differentiation marker 
in pRb-deficient myocytes. On the other hand, transfec- 
tion of pRb-deficient cells with high levels of ectopic p107 
or  p130  can  to  some  extent  augment  MyoD-mediated 
transactivation of MCK-CAT, suggesting that all members 
of the pRb family may share properties that promote mus- 
cle gene  expression. Although all members  of the  pRb 
family are known to interact with E2F transcription factor 
complexes, it is unclear whether this or other properties of 
these proteins are necessary to induce high-level muscle gene 
expression (see Gu et al., 1993a; Schneider et al., 1994). 
It is unclear why only some muscle genes require pRb 
for normal levels of expression. We have compared the 
ability of myogenic bHLH protein complexes from ceils 
containing or lacking pRb to specifically bind DNA in elec- 
trophoretic mobility-shift assays (EMSA) and have found 
that myogenic bHLH complexes from both cell types have 
similar affinity for DNA and identical mobility in EMSA 
(Novitch, B.G., and A.B. Lassar, data not shown). The dif- 
ferences in pRb sensitivity in early versus late differentia- 
tion markers may reflect either dissimilarities in the pro- 
moters of these two classes of muscle genes which render 
the former immune to the loss of pRb, or the activation of 
late differentiation markers by pRb-dependent myogenic 
regulators  that  are  themselves  expressed  at  later  times 
during the muscle differentiation program (i.e., myogenin, 
MRF-4, and MEF2). It may be relevant in this regard that 
the  pRb-mediated  boost  in  transactivation  of a  MCK- 
CAT reporter (which contains both an E  box and MEF2 
site) was much greater than that observed with an artificial 
reporter containing four reiterated E  boxes (a 23-35-fold 
versus a 3-10-fold increase in activity, respectively). It is 
interesting to note that a role for pRb in specifically pro- 
moting the  later  stages  of differentiation programs  has 
also been observed  during erythropoiesis (Clarke et al., 
1992; Jacks et al., 1992; Lee et al., 1992), neuronal differen- 
tiation (Lee et al., 1994), and in lens fiber cell formation 
(Morgenbesser et al.,  1994)  and that pRb has also been 
shown to activate the transcription factor NF-IL6, which is 
involved in macrophage differentiation (Chen et al., 1996). 
pRb Is Required to Maintain Terminal Go Arrest in 
Differentiated Myocytes 
It is clear from the results of the present study and from 
that of others (Schneider et al., 1994) that pRb plays a crit- 
ical role in preventing aberrant DNA synthesis in termi- 
at the indicated time points, and simultaneously immunostained 
for MHC and  the indicated proteins.  At least 300 cells of each 
MHC-staining  class  were  evaluated,  and  multinucleated  struc- 
tures were counted as single cells. (A) 10 tzM BrdU was added to 
the culture media, and cells were double stained for MHC and 
BrdU. The  percentage  of MHC-positive (O)  and  negative  (O) 
cells containing BrdU staining is indicated. For time zero, cells 
were maintained for an extra 6 h in the 0.1% FBS +  insulin me- 
dia before fixation. (B) Frequency of cyclin A  in MHC-positive 
(O) and -negative (O) cells. (C) Frequency of cyclin B in MHC- 
positive  (0)  and  -negative  (O)  cells.  (D)  Mitotic  activity  of 
MHC-positive  (O)  and  -negative  (O)  cells.  Mitotic cells were 
characterized by condensed chromosomes and formation of a mi- 
totic spindle. At least 1,000 cells of each MHC-staining class were 
evaluated for mitosis. 
Novitch et al. pRb in Myogenesis  451 Figure 8.  Differentiated pRb-deficient  myocytes over-express both cyclins and Cdks. pRb-deficient  MEFs infected with a retrovirus 
containing MyoD were differentiated for 3-4 d in media containing 0.1% FBS plus 10 p~g/ml insulin, serum-stimulated with media con- 
taining 20% FBS for 12-24 h, fixed in 2% paraformaldehyde,  and double stained for MHC (B, E, H, K, and N) and the indicated pro- 
teins. (A) Cyclin A, (D) cyclin B, (G) cyclin E, (J) Cdk2, and (M) Cdc2. Filled and open arrows indicate representative  MHC-positive 
and -negative cells, respectively, in each field. 
nally differentiated myocytes. In contrast to pRb-deficient 
myocytes  that  continue  to  synthesize  DNA,  myocytes 
lacking either p107 or p130 display normal Go arrest, indi- 
cating  that  pRb  can  maintain  terminal  cell  cycle  with- 
drawal  in  muscle  cells in  the  absence  of either p107  or 
p130. Whereas ectopic expression of either pRb or other 
pRb family members can inhibit DNA synthesis in pRb- 
deficient myocytes, neither endogenous expression of p21 
and p27 nor ectopic expression of p16 and p21 is sufficient 
to prevent DNA synthesis in these  ceils.  Recent studies 
have similarly found that the p16 family of Cdk inhibitors 
lack growth inhibitory function in cells lacking pRb (Guan 
et al., 1994; Koh et al., 1995; Lukas et al., 1995; Medema 
et  al.,  1995).  In  contrast,  p21,  p27,  and  p57  have  been 
shown to promote G1 accumulation, even in SAOS-2 cells 
which  lack  pRb  (Harper  et  al.,  1993;  Toyoshima  and 
Hunter 1994; Matsuoka et al., 1995). We surmise that the 
ability of p21 to induce G 1 accumulation in SAOS-2 cells 
but not inhibit DNA synthesis in differentiated pRb-defi- 
cient myocytes may be due to either methodological dif- 
ferences in  assay conditions  (i.e., flow cytometry versus 
BrdU uptake measurement) or inherent differences in the 
cell types. Furthermore, the absence of Go arrest in differ- 
entiated  pRb-deficient myocytes is  consistent  with  find- 
ings  that  overexpression  of  E2F-1  alone  can  promote 
DNA synthesis in serum-starved cells (Johnson et al., 1993; 
Qin  et  al.,  1994;  Shan  and  Lee  1994;  DeGregori et  al., 
1995b). Presumably by binding E2F/DP complexes, pRb 
silences transcription of genes  required for entry into  S 
phase,  and  therefore DNA  synthesis  is  promoted under 
The Journal of Cell Biology, Volume 135, 1996  452 Figure 9.  Caffeine administration induces mitotic catastrophe in differentiated pRb-deficient myocytes. Rb-/--MyoD cells were differ- 
entiated for 3 d in media containing 0.1% FBS plus 10 p~g/ml insulin and then stimulated  for 12 h with media containing 20% FBS. Cells 
were subsequently incubated for 6 additional  h in 20% FBS media containing  (A and B) or lacking (C and D) 5 mM caffeine, fixed in 
2% paraformaldehyde, and stained  with MHC antibodies  and DAPI. The filled arrow indicates  a "pulverized" nucleus seen in MHC- 
staining cells that were treated with caffeine, and the open arrow indicates a nondifferentiated cell undergoing  normal mitosis. 
normal Go conditions by either loss of pRb or overexpres- 
sion of E2F-I. 
pRb Loss in Differentiated Myocytes Leads to Abnormal 
S and G2 Phase Accumulation 
Although DNA synthesis was frequently observed in pRb- 
deficient myocytes, the kinetics of entry into S phase were 
attenuated in these cells in comparison to MHC-negative 
cells in the population. The slowed entry of MHC-positive, 
pRb-deficient myocytes into S phase may be due to high- 
level expression of p21  and p27 in these cells, which may 
Table I. Promotion of  Abnormal Mitosis in pRb-deficient 
Myocytes by Caffeine Treatment 
Normal  Nuclear 
mitosis  pulverization 
%  % 
MHC-positive 
-  Caffeine  0.8  0.4 
+  Caffeine  1.2  4.3 
MHC-negative 
-  Caffeine  1.4  0.0 
+  Caffeine  1.3  0.0 
Rb-/--MyoD cells were differentiated  for 4 d in media containing  0.1% FBS +  insu- 
lin, followed  by serum stimulation  with media containing  20% FBS for 12 h. High- 
serum media containing  or lacking  5 mM caffeine  was then  added,  and cells  were 
grown for an additional 6 h before fixation. Cells were stained for MHC and DNA us- 
ing antibodies  and DAPI, respectively,  and the number of MHC-positive  and -nega- 
tive cells containing  mitotic nuclei was evaluated.  See Fig. 9 for examples of the aber- 
rant mitosis observed. At least 500 MHC-positive  and -negative cells were counted for 
each culture condition. 
act to dampen Cdk-dependent  DNA synthesis. After se- 
rum stimulation,  the majority of pRb-deficient myocytes 
remained in S and G2 phase and did not readily progress 
into mitosis, as evidenced by the  accumulation of exces- 
sively high  amounts  of cyclins A  and  E,  Cdk2,  enlarged 
nuclei, and a DNA content of >2 N. The appearance of a 
>4 N DNA content in a subset of differentiated myocytes 
lacking  pRb  raises  the  possibility  that  the  failure  to 
progress through the cell cycle may allow these cells to un- 
dergo multiple rounds of replication. The lack of mitosis 
was not due to a failure of the cells to express Cdc2 or cy- 
clin B, as both proteins were present at elevated levels in 
pRb-deficient myocytes. Interestingly, the  mitotic block- 
ade in pRb-deficient myocytes could be overcome by caf- 
feine treatment, which is known to remove the inhibitory 
phosphorylations from Cdc2 and thereby promote mitosis 
(Steinmann et al., 1991; Smythe and Newport, 1992).  Caf- 
feine  treatment of the  differentiated  pRb-deficient myo- 
cytes led to a slight increase in the frequency of normal mi- 
tosis and dramatically increased the frequency of mitotic 
catastrophe.  Previous  studies  have  shown  that  caffeine 
promotes premature mitosis specifically in cells arrested in 
S that have accumulated both Cdc2 and cyclin B (Schlegel 
and  Pardee,  1986;  Steinmann  et al.,  1991);  thus,  the  caf- 
feine  sensitivity  of pRb-deficient  myocytes is  consistent 
with their accumulation in S and (32 phases. 
These findings suggest that, in the process of promoting 
muscle differentiation,  MyoD may positively regulate  an 
activity that either phosphorylates Cdc2 or negatively reg- 
ulates genes necessary for mitosis, such as the cdc25 phos- 
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Figure 10.  pRb  is  required 
for  the  expression  of  late 
markers of the skeletal mus- 
cle  differentiation  program 
and  for  permanent  with- 
drawal  from  the  cell  cycle. 
This  model  depicts  the pRb 
dependence  of  individual 
steps  of  the  skeletal  muscle 
differentiation program. Myo- 
blasts  expressing MyoD  are 
kept in a proliferating, nondifferentiated state by the actions of growth factors. After serum removal, MyoD becomes active and in- 
duces the expression of the early muscle differentiation markers myogenin and p21, in a manner that does not require pRb. In contrast, 
pRb is necessary for both high level expression of late muscle differentiation markers, such as myosin heavy chain, and the inhibition of 
DNA synthesis in differentiated myocytes. 
phatases, and thereby maintains the nonmitotic state. Al- 
though  incomplete DNA  replication and DNA  damage 
are both known to induce inhibitory phosphorylation of 
Cdc2 (for review see Nurse, 1994), it is unclear whether in- 
activation of this kinase in pRb-deficient myocytes is due 
to incomplete DNA replication or some other physiologi- 
cal signal in these cells. It is interesting to note that cyclin 
A ablation has been shown to activate Cdc2/cyclin B com- 
plexes and that introduction of cyclin A mRNA or protein 
can delay Cdc2-associated kinase activation (Walker and 
Mailer, 1991). It is therefore possible that the markedly el- 
evated cyclin A  protein levels in differentiated pRb-defi- 
cient myocytes may be related to the absence of mitosis. 
Another plausible explanation for the failure to progress 
to mitosis is the ability of MyoD to induce p21 in the ab- 
sence of pRb. In cycling Xenopus egg extracts, the addi- 
tion  of recombinant  p21  inhibits  the  kinase  activity of 
Cdk2, blocks mitosis, and leads to an accumulation of in- 
active Cdc2/cyclin B complexes (Guadagno and Newport, 
1996), similar to the phenotype of pRb-deficient myocytes. 
Moreover, expression of SV-40 T antigen has been found 
to induce DNA synthesis but not mitosis in senescent cells 
(Gorman  and  Cristofalo,  1985),  which  similarly  express 
high levels of p21 (Noda et al., 1994). 
The striking over-expression of cyclins A  and E, Cdk2, 
and Cdc2 concomitant with S phase arrest in differentiated 
pRb-deficient myocytes may reflect a defect in E2F-1/DP 
autoregulation in these cells. In the absence of pRb, E2F- 
1/DP complexes should be able to activate target genes, 
which include cyclin A, cyclin E, Cdc2, and other cell cy- 
cle-regulated  gene  products  (DeGregori,  et  al.,  1995a; 
Ohtani et al., 1995). During normal procession through S 
phase, E2F-1/DP activity is suppressed by association of 
E2F-1 with cyclin A/Cdk2 and consequent phosphoryla- 
tion of the DP subunit which disrupts the ability of E2F-1/ 
DP complexes to bind DNA (Krek et al., 1994). Failure of 
cyclin A/Cdk2 to inhibit E2F-1/DP activity has recently 
been shown to result in S phase arrest and subsequent apop- 
tosis of cells (Krek et al., 1995). We speculate that the in- 
creased levels of Cdk inhibitors like p21 and p27 in differ- 
entiated  myocytes lacking  pRb  may  interfere with  this 
regulatory loop by decreasing cyclin A/Cdk2 kinase activ- 
ity, which would thereby stabilize E2F-1/DP activity, lead- 
ing to both increased expression of E2F-l-regulated pro- 
teins  and  S  phase  arrest.  Since  we  have  not  observed 
significant levels of apoptosis in differentiated pRb-defi- 
cient myocytes (Novitch, B.G., and A.B. Lassar, data not 
shown), we surmise that hyperactive E2F complexes may 
only induce S phase arrest and not promote apoptosis in 
this unique cellular background. 
In summary, our findings and those of previous studies 
(Gu et al., 1993a; Schneider et al., 1994) indicate that pRb 
plays a critical role in both promoting high-level expres- 
sion  of end-stage markers  of the  muscle  differentiation 
program and in maintaining the G0-arrested state of myo- 
cytes. Moreover, a  pRb-independent mechanism  acts  to 
ensure that differentiated myotubes which enter S phase 
in the absence of pRb fail to readily progress into mitosis. 
It is interesting to note that in contrast to the relative ab- 
sence of mitosis in myocytes specifically lacking pRb, ex- 
pression  of viral  oncoproteins that  sequester  the  entire 
pRb family and other proteins efficiently promotes mitosis 
in differentiated myotubes (Fogel and Defendi, 1967; Yaffe 
and Gershon, 1967; Graessmann et al., 1973; Iujvidin et al., 
1990; Cardoso et al., 1993; Ohkubo et al., 1994; Crescenzi 
et al., 1995).  Taken together, these findings suggest that 
other  viral  oncoprotein-associated  proteins  (i.e.,  p300, 
p107, and p130) may have regulatory functions in control- 
ling S phase progression and mitosis, and that these viral 
oncoproteins can either negate these functions or extin- 
guish MyoD expression and thereby produce a mitotic cell 
cycle. 
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